Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 22;6(8):3334-47.
doi: 10.3390/v6083334.

Divergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particles

Affiliations

Divergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particles

Vladimir Temchura et al. Viruses. .

Abstract

A major advantage of virus-like particle (VLP) vaccines against HIV is their structural identity to wild-type viruses, ensuring that antigen-specific B-cells encounter the envelope protein in its natural conformation. For the induction of affinity-matured antibodies, the B-cells must also obtain help from T-cells that are restricted by linear epitopes. Using B- and T-cell transgenic mouse models, we compared the efficacy of modified HIV-VLPs delivered by subcutaneous and intravenous immunization to stimulate primary B- and T-cell proliferative responses in different lymphoid organs. VLPs containing an influenza virus hemagglutinin epitope within the HIV-Gag protein induced comparable primary cognate T-cell proliferative responses in the draining lymph node and the spleen, irrespective of the delivery route. In contrast, after subcutaneous immunization with HIV-Gag VLPs containing hen egg lysozyme (HEL) on their surface, the proliferative response of transgenic HEL-specific B-cells was restricted to the draining lymph nodes, while intravenous VLP immunization primarily induced a B-cell proliferative response in the spleen. In vitro co-culture experiments further revealed that the presentation of VLP-associated surface antigens by dendritic cells to cognate B-cells is inefficient. This is consistent with a direct triggering of the B-cell proliferative response by the VLPs and suggests that HIV VLPs may indeed be suitable to directly promote the expansion of B-cells specific for conformational epitopes that are unique to functionally-active Env spikes on the virion. Further investigations are warranted to explore potential differences in the quality and protective potency of HIV-specific antibody responses induced by the two routes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Design, production and characterization of HIV-virus-like particles (VLPs) containing an HA epitope. (A) Schematic representation of the Hgpsyn-HA and Hgsyn-HA expression cassettes. CMV, immediate early promoter of human cytomegalovirus; MA, matrix; CA, capsid; Pol, polymerase. HA110-120, influenza virus hemagglutinin epitope. (B) HEK293T cells were transfected with Hgpsyn, Hgpsyn-HA, Hgsyn or Hgsyn-HA. VLPs were recovered from the supernatants of transfected cells by ultracentrifugation through a sucrose cushion and analyzed by western blot with an antibody against capsid. (C) Naive untouched CD4+ T-cells were isolated from TCR-HA and BALB/c mice, labeled with CFSE and co-cultured with splenic DC at a 10:1 ratio for 64 h at 37 °C in the presence of the indicated VLPs (50 ng of capsid/mL). VLPs were prepared by co-transfection of an Env expression plasmid with one of the Gag or GapPol expression plasmids, as described in Table 1. After incubation, the cells were stained with anti-CD3 and anti-CD4 antibodies, and the CFSE fluorescence intensity of the CD3+ CD4+ cells is shown.
Figure 2
Figure 2
Proliferative response of naive cognate CD4+ T-cells after s.c. and i.v. immunization. Naive untouched CD4+ T-cells were isolated from TCR-HA mice labeled with CFSE and adoptively transferred into recipient BALB/c mice (2.5 × 106 cells per mouse). Four hours later, the recipient mice were immunized with GagPol-VLP-HA (s.c. or i.v.) or with Inflexal® V s.c. (A) Proliferation of the transferred CD4+ T-cells from the spleen and draining lymph nodes (LNs) was analyzed 72 h after immunization. The CFSE fluorescence intensity of CD3+ CD4+ is shown. (B) Expansion of transferred T-cells is evident by the increase in the percentage of CD4+ CFSE+ T-cells from total CD4+ lymphocytes in the spleen and lymph nodes. The histogram gives the mean of one experiment ± the standard deviation (n = 3). * Significant difference for the group in comparison to the other groups (p < 0.05; Student’s t-test). The experiment was repeated two more times with Gag-VLP-HA with similar results.
Figure 3
Figure 3
Proliferative response and expansion of naive cognate B-cells after s.c. and i.v. immunization. Naive untouched B-cells were isolated from SW-HEL mice, labeled with CFSE and adoptively transferred into recipient BL6 mice (5 × 106 cells per mouse). Four hours later, the recipient mice were immunized with HEL-VLP (s.c. or i.v.). (A) Three days later, spleen and LN cells were stained with Alexa647-conjugated HEL and anti-B220 antibodies. The CFSE fluorescence intensity of HEL+ B220+ cells is shown. (B) The expansion of HEL+ B220+ CFSE+ B-cells in draining LN on Day 3 is evident by the increase in their percentage of the total B220+ cells. The histogram gives the mean ± the standard deviation of one representative experiment (n = 4). Two independent experiments with three to four mice were performed. * Significant difference for the group comparison to the other groups (p < 0.05; Student’s t-test). (C, D) For the analyses of B-cell expansion on Day 7, non-labeled SW-HEL B-cells were transferred. Seven days after VLP injection, cells were stained with Alexa647-conjugated HEL and anti-B220 antibodies, and the expansion of HEL+ B220+ cells is presented as the percentage of the total B220+ cells (C) and as their absolute numbers in the cell preparations from spleen and lymph nodes (D). The histograms represent the mean within one experiment ± the standard deviation (n = 4). *** Significantly different from the other groups (p < 0.01; Student’s t-test). # Significantly different from the control group (p < 0.01; Student’s t-test).
Figure 4
Figure 4
Transfer of particulate and soluble HEL by DC to cognate B-cells in vitro. Naive untouched B2-cells were isolated from (A) SW-HEL and (B) BL6 mice and labeled with CFSE. Freshly isolated splenic DC or B-cells were separately incubated for 2 h in the presence of either HEL-VLP or mHEL. After extensive washing, DC and B-cells either exposed to VLPs/mHEL as marked by the “+” sign or non-exposed as marked by the “-” sign were mixed together and co-cultured for three days. The experiment was performed three times independently of each other, and one representative experiment is shown.

References

    1. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr. Opin. Immunol. 2010;22:358–366. doi: 10.1016/j.coi.2010.02.012. - DOI - PMC - PubMed
    1. McBurney S.P., Young K.R., Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology. 2007;358:334–346. doi: 10.1016/j.virol.2006.08.032. - DOI - PubMed
    1. Nabi G., Temchura V., Grossmann C., Kuate S., Tenbusch M., Uberla K. T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus. Retrovirology. 2012;9:42. doi: 10.1186/1742-4690-9-42. - DOI - PMC - PubMed
    1. Tong T., Crooks E.T., Osawa K., Robinson J.E., Barnes M., Apetrei C., Binley J.M. Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques. Virology. 2014;456–457:55–69. doi: 10.1016/j.virol.2014.03.015. - DOI - PubMed
    1. Cubas R., Zhang S., Kwon S., Sevick-Muraca E.M., Li M., Chen C., Yao Q. Virus-like particle (VLP) Lymphatic Trafficking and Immune Response Generation after Immunization by Different Routes. J. Immunother. 2009;32:118–128. doi: 10.1097/CJI.0b013e31818f13c4. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances